Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Staining of Phosphorylated Signalling Markers Protocol for Mass Cytometry.

Shinko D, Ashhurst TM, McGuire HM, Charles KA.

Methods Mol Biol. 2019;1989:139-146. doi: 10.1007/978-1-4939-9454-0_10.

PMID:
31077104
2.

Ecological risk based assessment used to restore riparian physical functions to a fresh water Creek.

Hall RK, Lin J, Schumacher BA, Charles KA, Heggem DT.

J Environ Manage. 2018 Sep 1;221:63-75. doi: 10.1016/j.jenvman.2018.03.117. Epub 2018 May 30.

PMID:
29859402
3.

Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease.

Charles KA, Naudet F, Bouali-Benazzouz R, Landry M, De Deurwaerdère P, Fossat P, Benazzouz A.

Mov Disord. 2018 Jul;33(6):1010-1015. doi: 10.1002/mds.27377. Epub 2018 May 18.

PMID:
29774960
4.

Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.

Shinko D, Diakos CI, Clarke SJ, Charles KA.

Clin Pharmacol Ther. 2017 Oct;102(4):599-610. doi: 10.1002/cpt.789. Epub 2017 Aug 24. Review.

PMID:
28699186
5.

Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients.

Charles KA, Harris BD, Haddad CR, Clarke SJ, Guminski A, Stevens M, Dodds T, Gill AJ, Back M, Veivers D, Eade T.

BMC Cancer. 2016 Feb 18;16:124. doi: 10.1186/s12885-016-2089-4.

6.

Fluorescent sensing of monofunctional platinum species.

Shen C, Harris BD, Dawson LJ, Charles KA, Hambley TW, New EJ.

Chem Commun (Camb). 2015 Apr 14;51(29):6312-4. doi: 10.1039/c4cc08077g.

PMID:
25760940
7.

Cancer-related inflammation and treatment effectiveness.

Diakos CI, Charles KA, McMillan DC, Clarke SJ.

Lancet Oncol. 2014 Oct;15(11):e493-503. doi: 10.1016/S1470-2045(14)70263-3. Review.

PMID:
25281468
8.

The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.

Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ.

Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30. doi: 10.1016/j.critrevonc.2013.03.010. Epub 2013 Apr 17. Review.

PMID:
23602134
9.

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.

Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH.

Pharmacogenomics. 2013 Jan;14(2):137-49. doi: 10.2217/pgs.12.202.

PMID:
23327575
10.

Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.

Elens L, Nieuweboer AJ, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, van Gelder T, Mathijssen RH, van Schaik RH.

Pharmacogenet Genomics. 2013 Mar;23(3):148-55. doi: 10.1097/FPC.0b013e32835dc113.

PMID:
23324807
11.

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR.

Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. Epub 2011 Nov 7.

12.

Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer.

Chua W, Clarke SJ, Charles KA.

Support Care Cancer. 2012 Aug;20(8):1869-74. doi: 10.1007/s00520-011-1289-3. Epub 2011 Oct 11.

PMID:
21986674
13.

Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

Chua W, Charles KA, Baracos VE, Clarke SJ.

Br J Cancer. 2011 Apr 12;104(8):1288-95. doi: 10.1038/bjc.2011.100. Epub 2011 Mar 29.

14.

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ.

Crit Rev Oncol Hematol. 2011 Sep;79(3):224-50. doi: 10.1016/j.critrevonc.2010.07.012. Epub 2010 Aug 16. Review.

PMID:
20719530
15.

Inflammation and cancer: causes and consequences.

Moore MM, Chua W, Charles KA, Clarke SJ.

Clin Pharmacol Ther. 2010 Apr;87(4):504-8. doi: 10.1038/clpt.2009.254. Epub 2010 Feb 10. Review.

PMID:
20147899
16.

Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.

Chua W, Moore MM, Charles KA, Clarke SJ.

Curr Opin Mol Ther. 2009 Dec;11(6):611-22. Review.

PMID:
20072938
17.

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T.

J Clin Invest. 2009 Oct;119(10):3011-23. doi: 10.1172/JCI39065. Epub 2009 Sep 8.

18.

"Re-educating" tumor-associated macrophages by targeting NF-kappaB.

Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR.

J Exp Med. 2008 Jun 9;205(6):1261-8. doi: 10.1084/jem.20080108. Epub 2008 May 19.

19.

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.

Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF.

Ann Oncol. 2008 Jul;19(7):1340-6. doi: 10.1093/annonc/mdn054. Epub 2008 Mar 5.

PMID:
18325912
20.

Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ.

Drug Metab Dispos. 2008 Feb;36(2):205-16. doi: 10.1124/dmd.107.018747.

PMID:
18218849
21.

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.

Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR.

Clin Cancer Res. 2006 Dec 15;12(24):7492-7.

22.

Predicting the toxicity of weekly docetaxel in advanced cancer.

Charles KA, Rivory LP, Stockler MR, Beale P, Beith J, Boyer M, Clarke SJ.

Clin Pharmacokinet. 2006;45(6):611-22.

PMID:
16719542
23.

Tumour necrosis factor-alpha as a tumour promoter.

Szlosarek P, Charles KA, Balkwill FR.

Eur J Cancer. 2006 Apr;42(6):745-50. Epub 2006 Mar 6. Review.

PMID:
16517151
24.

Smoldering and polarized inflammation in the initiation and promotion of malignant disease.

Balkwill F, Charles KA, Mantovani A.

Cancer Cell. 2005 Mar;7(3):211-7. Review. No abstract available.

25.

Factors affecting cytochrome P-450 3A activity in cancer patients.

Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A.

Clin Cancer Res. 2004 Dec 15;10(24):8341-50.

26.

The psychological impact of AIDS on gay men.

Morin SF, Charles KA, Malyon AK.

Am Psychol. 1984 Nov;39(11):1288-93.

PMID:
6507991

Supplemental Content

Loading ...
Support Center